Drug reaction with eosinophilia and systemic symptoms (DRESS) / drug-induced hypersensitivity syndrome (DIHS): A review of current concepts;reacao a drogas com eosinofilia e sintomas sistemicos (DRESS) / sindrome da hipersensibilidade induzida por droga (DIHS): Revisao dos conceitos atuais

Anais Brasileiros de Dermatologia

Volumn 87, Issue 3, 2012, Pages 435-449

  Criado, Paulo Ricardo ^a   Criado, Roberta Fachini Jardim ^b   Avancini, Joao de Magalhaes ^a   Santi, Claudia Giuli ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE MEDICINA DO ABC   (Brazil)

Author keywords

Drug eruptions; Drug hypersensitivity; Eosinophilia

Indexed keywords

ABACAVIR; AMITRIPTYLINE; CARBAMAZEPINE; CIDOFOVIR; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DESIPRAMINE; DICLOFENAC; ETHOSUXIMIDE; FLUOXETINE; GANCICLOVIR; HLA ANTIGEN; IBUPROFEN; LAMOTRIGINE; LINEZOLID; MEXILETINE; MINOCYCLINE; NAPROXEN; NEVIRAPINE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; PRIMIDONE; SALAZOSULFAPYRIDINE; TERBINAFINE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DRESS SYNDROME; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INCIDENCE; LABORATORY TEST; MEDLINE; MORTALITY; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SKIN MANIFESTATION; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

DRUG HYPERSENSITIVITY; EOSINOPHILIA; HUMANS; SYNDROME;

EID: 84863108366     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962012000300013     Document Type: Review

References (70)

1. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash With Eosinophilia and Systemic Symptoms: DRESS). Sem Cutan Med Surg. 1996;1:250-257.
2. Chaiken B, Goldberg B, Segal J. Dilantin hypersensitivity: report of a case of hepatitis with jaundice, pyrexia, and exfoliative dermatitis. N Engl J Med. 1950;242:897-898.
3. Walsh SA, Creamer D. Drug reaction with eosinophila and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2010;36:6-11.
4. Piñana E, Lei SH, Merino R, Melgosa M, De La Vega R, Gonzales-Obeso E, et al. DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpevirus 6 in an 11-year-old Caucasian boy. J Clin Pharm Ther. 2010;35:365-370.
5. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest. 1988;82:1826-1832.
6. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149:1018-1022.
7. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy. 2007;27:1425-1439.
8. Ganeva M, Gancheva T, Lazarova R, Troeva J, Baldaranov I, Vassilev I, et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol. 2008;47:853-860.
9. Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clinic Rev Allerg Immunol. 2007;33:124-133.
10. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS Syndrome: a literature review. Am J Med. 2011;124:588-597.
11. Sullivan JR, Shear NH. The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol. 2001;137:357-364.
12. Ruble J. Matsuo H. Anticonvulsant-induced cutaneous reactions. Incidence, mechanisms and management. CNS Drugs. 1999;12:215-236.
13. Santiago F, Gonçalo M, Vieira R, Coelho S, Figueiredo A. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis. 2010;62:47-53.
14. Jurado-Palomo J, Cabañas R, Prior N, Bobolea ID, Fiandor-Román AM, López-Serrano MC, et al. Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: two case reports. J Investig Allergol Clin Immunol. 2010;20:433-436.
15. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clone. Mol Pharmacol. 2003;63:732-741.
16. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T-cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393-1403.
17. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and anti-drug immune responses. Allergol Int. 2006;55:1-8.
18. Picard D, Janela B, Descamps V, D'Incan M, Courville P, Jacquot S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010;2:46-62.
19. Oskay T, Karademir A, Ertürk OI. Association of anticonvulsant hypersensitivity syndrome with Herpesvirus 6,7. Epilepsy Res. 2006;70:27-40.
20. Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol. 2006;155:344-349.
21. Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol. 2006;155:301-306.
22. Wu Y, Sanderson JP, Farrel J, Drumong NS, Hanson A, Bowkett E, et al. Activation of T cells by carbamazepine na carbamazepine metabolites. J Allergy Clin Immunol. 2006;118:233-241.
23. Katsafanas GC, Schirmer EC, Wyatt LS, Frenkel N. In vitro activation of human herpesvirus 6 and 7 from latency. Proc Natl Acad Sci USA. 1996;93:9788-9792.
24. Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol. 2004;140:183-188.
25. Gentile I, Talamo M, Borgia G. Is the drug-induced hypersensitivity syndrome (DIHS) due to herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review. BMC Infectious Dis. 2010;10:49.
26. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial ocorrence of hypersensitivity to phenytoin. Am J Med. 1991;91:631-634.
27. Hall CB, Caserta MT, Schnabel K, Shelley LM, Marino AS, Carnahan JA, et al. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics. 2008;122:513-520.
28. Watanabe H, Daibata M, Tohyama M, Batchelor J, Hashimoto K, Iijima M. Chromosomal integration of human herpesvirus 6 DNA in anticonvulsant hypersensitivity syndrome. Br J Dermatol. 2008;158:640-642.
29. Aihara Y, Ito SI, Kobayashi Y, Yamakawa Y, Aihara M, Yokota S. Carbamazepineinduced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by realtime quantitative polymerase chain reaction. Br J Dermatol. 2003;149:165-169.
30. Yoshikawa T, Fujita A, Yagami A, Suzuki K, Matsunaga K, Ihira M, et al. Human herpesvirus 6 reactivation and inflammatory cytokine production in patients with druginduced hypersensitivity syndrome. J Clin Virol. 2006;37 Suppl 1:S92-S96.
31. Tohyama M, Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. J Dermatol. 2011;38:228-228.
32. Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182:8071-8079.
33. Sugita K, Tohyama M, Watanabe H, Otsuka A, Nakajima S, Iijima M, et al. Fluctuation of blood and skin plasmacytoid dendritic cells in drug-induced hypersensitivity syndrome. J Allergy Clin Immunol. 2010;126:408-410.
34. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284:1835-1837.
35. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5:1219-1226.
36. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. 2007;156:1083-1084.
37. Demoly P, Viola M, Gomes ER, Romano A. Epidemiology and causes of drug hypersensitivity. In: Pichler WJ, editor. Drug hypersensitivity. Basel: Karger; 2007.p.2-17.
38. Aihara M. Pharmacogenetics of cutaneous adverse drug reactions. J Dermatol. 2011;38:246-254.
39. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48:1015-1018.
40. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49:2087-2091.
41. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006;16:297-306.
42. Alfirevic A, Jorgensen AL, Wiliamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006;97:813-818.
43. Kano Y, Hirahara K, Asano Y, Shiohara T. HLA-B allele associations with certain drug are not confirmed in Japanese patients with severe cutaneous drug reactions. Acta Derm Venereol. 2008;88:616-618.
44. Tokunaga k, Ishikawa Y, Ogawa A, Wang H, Mitsunaga S, Moriyama S, et al. Sequence based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics. 1997;46:199-205.
45. Kashiwagi M, Aihara M, Takahashi Y, Yamazaki E, Yamane Y, Song Y, et al. Human leukocyte antigen genotypes in carbamazepine induced severe cutaneous adverse drug response in Japanese patients. J Dermatol. 2008;35:683-685.
46. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse drug reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102:4134-4139.
47. Dainichi T, Uchi H, Moroi Y, Furue M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology. 2007;215:86-88.
48. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology. 2001;56:890-896.
49. Ronaldson KJ, McNeil JJ. Improving drug safety by locating genetic markers for hypersensitivity reactions. Med J Aust. 2009;190:641-643.
50. Fernando SL, Henderson CJ, O'Connor KS. Drug-induced hypesensitivity syndrome with superficial granulomatous dermatites - a novel finding. Am J Dermatopathol. 2009;31:611-613.
51. Criado PR, Lucena SK, Crivellaro APGS, Criado RFJ, Tebcherani A, Nogueira AT, et al. Síndrome de hipersensibilidade a anticonvulsivantes: relato de dois casos. Rev Bras Clin Terap. 2002;28:59-63.
52. Aires NB, Criado PR, Vilela MAC, Romiti R, Belda Junior W, Sotto MN, et al. Síndrome de hipersensibilidade a anticonvulsivantes: relato de três casos. Diagn Tratamento. 2006;11:86-90.
53. Criado PR, Criado RF, Vasconcellos C, Pegas JR, Cera PC. Drug-induced hypersensitivity syndrome due to anticonvulsants in a two-year-old boy. J Dermatol. 2004;31:1009-1013.
54. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med. 1995;155:2285-2290.
55. Chang DKM, Shear NH. Cutaneous reactions to anticonvulsants. Semin Neurol. 1992; 12:329-337.
56. Silvares MRC, Abbade LPF, Lavezzo M, Gonçalves TM, Abbade J. Reações cutâneas desencadeada por drogas. An Bras Dermatol. 2008;83:227-232.
57. Viera MH, Perez OA, Patel JK, Jones I, Berman B. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS. Cutis. 2010;85:312-317.
58. Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, et al. Twelve year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2009;145:67-72.
59. Kano Y, Ishida T, Hirahara K, Shiohara T. Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome. Med Clin N Am. 2010;94:743-759.
60. Lens S, Crespo G, Carrión JA, Miguel R, Navasa M. Severe acute hepatitis in the DRESS syndrome: report of two cases. Ann Hepatol. 2010;9:198-201.
61. Kennebeck GA. Anticonvulsant hypersensitivity syndrome. J Am Board Fam Pract. 2000;13:364-370.
62. Fittje M. Anticonvulsant hypersensitivity syndrome. Int J Neurol. 2001;1(1).
63. Kosseifi SG, Guha B, Nassour DN, Chi DS, Krishnaswamy G. The Dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol. 2006;1:9.
64. Asano Y, Kagawa H, Kano Y, Shiohara T. Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with druginduced hypersensitivity syndrome. Arch Dermatol. 2009;145:1030-1036.
65. Ang CC, Wang YS, Yoosuff EVM, Tay YK. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol. 2010;63:219-227.
66. Sontheimer RD, Houpt KR. DIDMOHS. A proposed nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol. 1998;134:874-876.
67. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609-611.
68. Descamps V, Ben-Saïd B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, et al. Management of drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol. 2010;137:703-708.
69. Criado PR, Criado RFJ, Vasconcellos C, Ramos RO, Gonçalves AC. Reações cutâneas graves adversas a drogas - Aspectos relevantes ao diagnóstico e ao tratamento - Parte II. An Bras Dermatol. 2004; 79:587-601.
70. Kito Y, Ito T, Tokura Y, Hashizume H. High-dose intravenous immunoglobulin monotherapy for drug-induced hypenssensitivity syndrome. Acta Derm Venereol. 2012;92:100-101.